Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Fintel reports that on March 19, 2025, Rodman & Renshaw initiated coverage of BioXcel Therapeutics (NasdaqCM:BTAI) with a Buy ...

AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, ...

Checkpoint inhibitors such as tislelizumab ... towards realizing the full potential of its Decoy platform. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances.

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results ...

TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.

Combining checkpoint inhibitors with immune system activators like Decoy20 could provide a more powerful and sustained anti-tumor response. Indaptus Therapeutics has evolved from more than a century ...